title: [Situation of long-term use of oral anticoagulation among atrial fibrillation patients with stroke in different level hospital].
abstract: OBJECTIVE
  To investigate the current situation, time trends and factors associated with long-term use of oral anticoagulation (OAC) among atrial fibrillation (AF) patients with ischemic stroke.
  
  
  METHODS
  We used the dataset from the CAFR (Chinese Atrial Fibrillation Registry), a prospective, multicenter, hospital-based registry study involving 20 tertiary and 12 nontertiary hospitals in Beijing. In brief, 380 consecutive AF patients with following ischemic stroke were enrolled from 2003 to 2014.Patients with valvular AF, radiofrequency catheter ablation history or contraindications of OAC were excluded. We divided the patients into two groups according to hospital level, and investigated the rate of OAC use and its change over time in patients who had indication, the factors including patient characteristics and hospital level associated with OAC use were also analyzed.
  
  
  RESULTS
  Overall oral anticoagulation use rate was 27.71%, which dropped to 22.11% and 15.26% at 6 months and 12 months, respectively.A total of 298 participates were enrolled from tertiary hospitals (78.42%), and 82 were enrolled from nontertiary hospitals. The status of OAC use in tertiary hospitals was better than nontertiary hospitals (32.66% vs 7.32%, P<0.001). Multivariable analysis showed better oral anticoagulation use was independently associated with higher-level hospitals (odds ratio 1.785, 95% confidence interval 1.026-3.106, P=0.040), and history of heart failure (odds ratio 2.247, 95% confidence interval 1.235-4.090, P=0.008).
  
  
  CONCLUSIONS
  These data indicates oral anticoagulation use has improved in atrial fibrillation patients with stroke in Beijing. The use of anticoagulation among the patients from tertiary hospitals is significantly better than those from nontertiary hospitals, and the history of heart failure may have effect on the use of oral anticoagulation.
authors.affiliation: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing 100029, China.
authors.forename: R
authors.initials: R
authors.lastname: Jing
authors.forename: X Y
authors.initials: XY
authors.lastname: Guo
authors.forename: S J
authors.initials: SJ
authors.lastname: Xia
authors.forename: S S
authors.initials: SS
authors.lastname: Chang
authors.forename: J Y
authors.initials: JY
authors.lastname: Li
authors.forename: S X
authors.initials: SX
authors.lastname: Lu
authors.forename: X
authors.initials: X
authors.lastname: Du
authors.forename: J Z
authors.initials: JZ
authors.lastname: Dong
authors.forename: C S
authors.initials: CS
authors.lastname: Ma
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants; D001281:Atrial Fibrillation; D017115:Catheter Ablation; D006761:Hospitals; D006801:Humans; D011446:Prospective Studies; D012042:Registries; D020521:Stroke; D013997:Time Factors
chemical_list: D000925:Anticoagulants